DE69934689T2 - Verwendung der protein-kinase-c-epsilon-inhibitoren zur behandlung von schmerzen - Google Patents

Verwendung der protein-kinase-c-epsilon-inhibitoren zur behandlung von schmerzen Download PDF

Info

Publication number
DE69934689T2
DE69934689T2 DE69934689T DE69934689T DE69934689T2 DE 69934689 T2 DE69934689 T2 DE 69934689T2 DE 69934689 T DE69934689 T DE 69934689T DE 69934689 T DE69934689 T DE 69934689T DE 69934689 T2 DE69934689 T2 DE 69934689T2
Authority
DE
Germany
Prior art keywords
pkcε
inhibitor
pain
hyperalgesia
epinephrine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69934689T
Other languages
German (de)
English (en)
Other versions
DE69934689D1 (de
Inventor
Robert O. Foster City Messing
Jon D. San Francisco Levine
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, University of California Berkeley, University of California San Diego UCSD filed Critical University of California
Publication of DE69934689D1 publication Critical patent/DE69934689D1/de
Application granted granted Critical
Publication of DE69934689T2 publication Critical patent/DE69934689T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
DE69934689T 1998-07-06 1999-07-06 Verwendung der protein-kinase-c-epsilon-inhibitoren zur behandlung von schmerzen Expired - Lifetime DE69934689T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US9175598P 1998-07-06 1998-07-06
US91755P 1998-07-06
US10376398P 1998-10-09 1998-10-09
US103763P 1998-10-09
PCT/US1999/015265 WO2000001415A2 (en) 1998-07-06 1999-07-06 Use of inhibitors of protein kinase c epsilon to treat pain

Publications (2)

Publication Number Publication Date
DE69934689D1 DE69934689D1 (de) 2007-02-15
DE69934689T2 true DE69934689T2 (de) 2007-10-25

Family

ID=26784298

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69934689T Expired - Lifetime DE69934689T2 (de) 1998-07-06 1999-07-06 Verwendung der protein-kinase-c-epsilon-inhibitoren zur behandlung von schmerzen

Country Status (10)

Country Link
EP (1) EP1093379B1 (https=)
JP (1) JP2002519391A (https=)
AT (1) ATE350032T1 (https=)
AU (1) AU764760B2 (https=)
CA (1) CA2336709A1 (https=)
DE (1) DE69934689T2 (https=)
ES (1) ES2283120T3 (https=)
IL (1) IL140716A0 (https=)
NZ (1) NZ508767A (https=)
WO (1) WO2000001415A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7790192B2 (en) 1998-08-14 2010-09-07 Accessclosure, Inc. Apparatus and methods for sealing a vascular puncture
AU2003234185C1 (en) 2002-04-22 2009-11-19 The Board Of Trustees Of The Leland Stanford Junior University Peptide inhibitors of protein kinase C
US6933275B2 (en) 2002-05-01 2005-08-23 The Board Of Trustees Of The Leland Stanford Junior University Protein kinase C peptides for use in withdrawal
WO2004084889A1 (en) * 2003-03-28 2004-10-07 Pfizer Inc. Use of protein kinase c inhibitor for suppressing sustained slow postsynaptic excitation (sspe) of enteric neurons
EP1631309A4 (en) * 2003-05-16 2010-04-28 Univ Leland Stanford Junior Protein kinase c peptides for use in withdrawal
EP1670497A4 (en) 2003-09-16 2009-07-15 Garvan Inst Med Res METHOD FOR IDENTIFYING MODULATORS OF PROTEIN KINASE C EPSILON (PKC Ε) AND METHOD FOR TREATING THEREOF CONVERTING DERIVED GLUCOSE METABOLISM
WO2006095086A2 (fr) * 2005-03-07 2006-09-14 Laurence Faure Traçabilite des anomalies du cycle cellulaire ciblant l'oncologie et la neurodegenerescence.
EP1869205B1 (en) * 2005-04-02 2010-07-14 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Assays for determining compounds which modulate tram phosphorylation
US8575307B2 (en) 2005-06-29 2013-11-05 Hadasit Medical Research Services & Development Ltd. Protein kinase C inhibitors for prevention of insulin resistance and type 2 diabetes
EP2177510A1 (en) 2008-10-17 2010-04-21 Universität des Saarlandes Allosteric protein kinase modulators
JP2010090176A (ja) * 2010-01-26 2010-04-22 Board Of Trustees Of The Leland Stanford Junior Univ 離脱症状における使用のためのプロテインキナーゼｃペプチド
US8785648B1 (en) 2010-08-10 2014-07-22 The Regents Of The University Of California PKC-epsilon inhibitors
WO2014081029A1 (ja) * 2012-11-26 2014-05-30 学校法人近畿大学 抗がん剤による末梢神経障害の予防、治療、または軽減剤
EP3180003B1 (en) 2014-07-01 2022-01-12 The Regents of the University of California Pkc-epsilon inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141957A (en) * 1990-11-02 1992-08-25 Sphinx Pharmaceuticals Corporation 1,4-bis-(amino-hydroxyalkylamino)-anthraquinones for inhibiting protein kinase c
US5783405A (en) * 1994-02-01 1998-07-21 Terrapin Technologies, Inc. Rapid screening method for effectors of signal transduction
WO1997015575A1 (en) * 1995-10-27 1997-05-01 Procyon Pharmaceuticals, Inc. Protein kinase c modulators. y.

Also Published As

Publication number Publication date
ES2283120T3 (es) 2007-10-16
AU4863199A (en) 2000-01-24
EP1093379A2 (en) 2001-04-25
WO2000001415A2 (en) 2000-01-13
WO2000001415A3 (en) 2000-04-13
JP2002519391A (ja) 2002-07-02
EP1093379B1 (en) 2007-01-03
DE69934689D1 (de) 2007-02-15
ATE350032T1 (de) 2007-01-15
AU764760B2 (en) 2003-08-28
IL140716A0 (en) 2002-02-10
CA2336709A1 (en) 2000-01-13
NZ508767A (en) 2003-12-19

Similar Documents

Publication Publication Date Title
Baluk Neurogenic inflammation in skin and airways
US6686334B2 (en) Use of inhibitors of protein kinase C epsilon to treat pain
DE69934689T2 (de) Verwendung der protein-kinase-c-epsilon-inhibitoren zur behandlung von schmerzen
Suzuki et al. Superficial NK1-expressing neurons control spinal excitability through activation of descending pathways
Dmitrieva et al. Sensitisation of visceral afferents by nerve growth factor in the adult rat
Holland et al. Orexin 1 receptor activation attenuates neurogenic dural vasodilation in an animal model of trigeminovascular nociception
Akerman et al. Anandamide is able to inhibit trigeminal neurons using an in vivo model of trigeminovascular-mediated nociception
DE69627963T2 (de) Verbesserte zusammensetzungen und verfahren zur chemodenervation mit neurotoxinen
Johnson et al. Evaluation of the permanent sympathectomy produced by the administration of guanethidine to adult rats.
Carlton et al. Somatostatin modulates the transient receptor potential vanilloid 1 (TRPV1) ion channel
Décosterd et al. Intrathecal implants of bovine chromaffin cells alleviate mechanical allodynia in a rat model of neuropathic pain
de Souza et al. An evaluation of the antinociceptive effects of Phα1β, a neurotoxin from the spider Phoneutria nigriventer, and ω-conotoxin MVIIA, a cone snail Conus magus toxin, in rat model of inflammatory and neuropathic pain
DE69715862T2 (de) Verwendung eines k-252a derivats zur behandlung von periphärer oder zentraler nervenerkrankungen und übermässiger cytokinbildung
Meidahl et al. Intranasal oxytocin attenuates reactive and ongoing, chronic pain in a model of mild traumatic brain injury
Ren et al. Inflammation and hyperalgesia in rats neonatally treated with capsaicin: effects on two classes of nociceptive neurons in the superficial dorsal horn
Wamil et al. Phenytoin blocks N-methyl-D-aspartate responses of mouse central neurons.
Gold et al. Cortical spreading depression-associated hyperemia in rats: involvement of serotonin
Khalili et al. Caffeine increases paragigantocellularis neuronal firing rate and induces withdrawal signs in morphine-dependent rats
Kimura et al. Glial cell line‐derived neurotrophic factor‐mediated enhancement of noradrenergic descending inhibition in the locus coeruleus exerts prolonged analgesia in neuropathic pain
Layer et al. Effect of serotonergic agonists in the nucleus accumbens on d-amphetamine-stimulated locomotion
Yonehara et al. Involvement of NMDA–nitric oxide pathways in the development of tactile hypersensitivity evoked by the loose-ligation of inferior alveolar nerves in rats
Haghparast et al. Morphine tolerance and dependence in the nucleus paragigantocellularis: single unit recording study in vivo
EP1255538B1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
Deffenu et al. Acetylcholine and 5-hydroxytryptamine levels of the lateral geniculate bodies and superior colliculus of cats after visual deafferentation
Rudd et al. Genital grooming and emesis induced by vanilloids in Suncus murinus, the house musk shrew

Legal Events

Date Code Title Description
8364 No opposition during term of opposition